Teva Loses Decision on Validity of Third Copaxone PatentBy
Mylan, Amneal win patent office ruling on Teva’s MS drug
Two other patents were already deemed invalid by U.S. agency
Teva Pharmaceutical Industries Ltd. had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated Thursday by a U.S. agency, a further blow to its bid to block generic versions of a drug that accounts for 20 percent of its revenue.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.